CUPERTINO, Calif., Nov. 2, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2015. Total revenues were $4.7 million and net loss was $6.5 million for the three months ended September 30, 2015 as compared to total revenues of $4.3 million and net loss of $7.1 million for the three months ended September 30, 2014.
At September 30, 2015, we had cash and investments of $32.4 million, compared to cash and investments of $34.9 million at December 31, 2014. At September 30, 2015, we had $19.7 million in long term debt.
“We continued to make solid progress on multiple fronts since last quarter,” stated James E. Brown, D.V.M., President and CEO of DURECT. “We recently began recruiting patients in our POSIMIR pivotal Phase 3 clinical trial which is intended to provide the data necessary for a robust NDA resubmission. For DUR-928, the single-ascending-dose Phase 1 trial with our injectable formulation reported no treatment related adverse events such that we are moving on to the multiple-dose Phase 1 trial, and today we are reporting positive data from a leptin deficient rat model, which is the 8th preclinical model to demonstrate a positive effect when administering DUR-928. Regarding Relday, Zogenix reported positive results from their Phase 1b multi-dose clinical trial such that they are initiating efforts to secure a partner for Relday which is now positioned for Phase 3.”
Update of Selected Programs:
- POSIMIR (SABER®-Bupivacaine, also previously known as POSIDUR) Post-Operative Pain Relief Depot. We recently began recruiting patients for PERSIST, the POSIMIR pivotal Phase 3 clinical trial. PERSIST is planned to involve slightly over 300 patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery. These patients will be randomized on a one-to-one basis to receive either POSIMIR or placebo as a one-time intra-incisional instillation at the time of surgery. In a previous clinical trial of 50 patients undergoing laparascopic cholecystectomy, POSIMIR was compared with the active control bupivacaine hydrochloride, against which POSIMIR demonstrated an approximately 25% reduction in pain intensity on movement for the first 3 days after surgery (p=0.024), using the same statistical methodology specified for the current trial. We believe that PERSIST represents the first pivotal efficacy trial in this category in a laparoscopic procedure. We expect that it will take approximately one year to complete patient enrollment in PERSIST. This clinical trial is based on multiple interactions with the FDA and is designed to generate data necessary to support an NDA resubmission.
POSIMIR is our investigational post-operative pain relief depot that utilizes our patented SABER technology and is intended to deliver bupivacaine to provide 3 days of pain relief after surgery. We are in discussions with potential partners regarding licensing development and commercialization rights to POSIMIR, for which we hold worldwide rights. We are also continuing to evaluate the requirements for commercializing POSIMIR on our own in the U.S., in the event that we determine that to be the preferred route of commercialization.
- Epigenomic Regulator Program. DUR-928, our Epigenomic Regulator Program’s lead product candidate, is an endogenous, small molecule, new chemical entity (NCE), which may have broad applicability in several metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury.
Previously we communicated that the biological activity of DUR-928 has been demonstrated in 7 different animal disease models involving three animal species. Four of these models represent acute organ injury (endotoxin shock, kidney, liver and brain) and three represent chronic disorders of hepatic lipid accumulation and dysfunction (e.g., NAFLD and NASH). Today we are reporting that DUR-928 reduced lipid accumulation in the liver in a leptin deficient Zucker rat model. In this study, 3 weeks of daily treatment by oral administration of DUR-928 significantly reduced hepatic triglyceride, total cholesterol as well as free fatty acids levels. Liver morphology and lipidosis were also noticeably improved, consistent with biochemical changes. The data from this model provides further support to our other animal models and is suggestive of DUR-928’s potential use in chronic metabolic disorders.
In addition, in August 2015 we commenced a Phase 1 single-site, randomized, double-blinded, placebo-controlled, single-ascending-dose study that evaluated the safety, tolerability and pharmacokinetics of DUR-928 when administered by injection. The 18-subject study evaluated DUR-928 in three cohorts of healthy volunteers receiving DUR-928 at escalating doses that resulted in peak plasma concentrations at least 100-fold higher than endogenous levels. DUR-928 was well-tolerated at all dose levels, with no treatment-related adverse events reported. DURECT is now moving on to a multiple-dose Phase 1 trial with the injectable formulation. Assuming no adverse safety results from this trial, DURECT would then be positioned to commence patient trials in 2016 with an injectable formulation as well as with an oral formulation.
- REMOXY (oxycodone) Extended-Release Capsules CII. Based on our ORADUR® technology, REMOXY is a unique long-acting formulation of oxycodone designed to discourage common methods of tampering associated with opioid misuse and abuse. In May 2015, Pain Therapeutics (our licensee) stated that the transition of REMOXY back from Pfizer was substantially complete, and in July 2015 they stated that they expect to resubmit the NDA in the first quarter of 2016. The extended release oxycodone market is ~$2.4 billion in the U.S. alone, and we are eligible for a potential royalty on REMOXY between 6.0% to 11.5% of net sales depending on sales volumes.
- Relday (Risperidone Program). Relday is a proprietary, long-acting, once-monthly subcutaneous injectable formulation of risperidone for the treatment of schizophrenia. To provide context, an existing long-acting injectable risperidone product that achieved $1.2 billion in global net sales in 2014 requires drug reconstitution prior to use and twice-monthly, intramuscular injections. Zogenix (our licensee) has previously announced positive results from a single-dose Phase 1 clinical trial of Relday at the full dose range anticipated to be used in clinical practice. In September 2015, Zogenix announced positive top-line results from a Phase 1b multi-dose parallel group clinical trial that enrolled 60 subjects. According to Zogenix, the trial results for Relday demonstrated that risperidone plasma concentrations in the therapeutic range were achieved on the first day of dosing, reached steady state levels following the second dose and consistently maintained therapeutic levels throughout the four-month period. Also according to Zogenix, Relday was generally safe and well-tolerated, with results consistent with the profile of risperidone and the previous Phase 1 single-dose clinical trial. Zogenix further stated that it has now initiated efforts to secure a development and commercialization partner for Relday, and that Relday is well-positioned to begin a Phase 3 program once a partner is secured.
ORADUR-ADHD Program. In 2013, we selected a formulation for the lead program in our ORADUR-ADHD (Attention Deficit Hyperactivity Disorder) program, ORADUR-Methylphenidate.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
